Medullary Thyroid Cancer Secreting Carbohydrate Antigen 19-9 (Ca 19-9): A Fatal Case Report

Abstract

High levels of serum Ca 19-9 could be considered a marker of the dedifferentiation of MTC and disease aggressiveness, but additional data on the association between Ca 19-9 and advanced MTC are required to confirm this hypothesis.

Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer

“…Recently we observed a peculiar case of aggressive MTC in a young patient with MEN2A who rapidly died of neoplasia (23). High serum levels of Ca 19.9, which is typically considered a gastrointestinal tumor marker (26), were present.…”

“…Recently, the case of a 56-year-old woman with MEN2B and high serum levels of Ca 19.9 and the case of a young man with MEN2A who exhibited high and progressively increasing serum levels of Ca 19.9 have been reported (22,23) and the possibility that high levels of serum Ca 19.9 could be a prognostic factor of poor prognosis has been suggested.…”

Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors

“…Conversely, in view of its abnormal increased expression level in common pancreatic cancer; CA19-9 has been used as a diagnostic marker to differentiate pancreatic cancer from pNETs (15,16). However, few previous studies have demonstrated that CA19-9 may be used as a prognostic biomarker in neuroendocrine tumors (17,18). For example, Elisei et al (17) reported a case of multiple endocrine neoplasia type 2B with significant elevation of CA19-9 expression levels.…”

“…However, few previous studies have demonstrated that CA19-9 may be used as a prognostic biomarker in neuroendocrine tumors (17,18). For example, Elisei et al (17) reported a case of multiple endocrine neoplasia type 2B with significant elevation of CA19-9 expression levels. The patient experienced rapid disease progression and survived for only a short period, indicating that CA19-9 may be a biomarker of aggressiveness (17).…”

“…For example, Elisei et al (17) reported a case of multiple endocrine neoplasia type 2B with significant elevation of CA19-9 expression levels. The patient experienced rapid disease progression and survived for only a short period, indicating that CA19-9 may be a biomarker of aggressiveness (17). A further study conducted by Elisei et al (18) revealed that 16/100 advanced structural recurrent/persistent medullary thyroid cancer tissues exhibited high expression levels of CA19-9, and the CA19-9 positive group demonstrated a higher mortality rate compared with the normal CA19-9 expression group.…”